Rapacuronium

• Catalog No.: DB04834
• CAS Number: 156137-99-4
• M. F.: C37H61BrN2O4
• M. W.: 677.79524

SYNONYMS

• IUPAC name: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium bromide
• IUPAC Traditional name: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium bromide
• Brand Name: Raplon
• Synonyms: Rapacuronium bromide

DATABASE IDS

• PubChem SID: 46506932
• PubChem CID: 5311398
• CAS Number: 156137-99-4

DETAILS

Description (English)

• Drug Groups: withdrawn
• Description: Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
• Indication: Used in anaesthesia, to aid and enable endotracheal intubation.
• Pharmacology: Rapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hydrolyzed to active metabolites (Cytochrome P450 system is not involved).
• Half Life: 141 minutes (mean)
• Protein Binding: Variable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protein to which rapacuronium binds is unknown. Plasma protein binding of the 3-hydroxy metabolite was not determined.
• External Links: Wikipedia; RxList